How Does Capromorelin Work? Mechanism of Action, Per the Research

The short version of the mechanism

Capromorelin is a prescription medicine in veterinary practice, characterised across the published pharmacology literature as an orally active agonist at the ghrelin receptor, with a review of its discovery, efficacy, safety and clinical applications describing it in exactly those terms (PMID 37493940). Its receptor target is the growth hormone secretagogue receptor type 1a, usually abbreviated GHSR-1a, which is the same receptor that the endogenous stomach-derived hormone ghrelin activates. A veterinary pharmacology paper on capromorelin as an appetite stimulant in dogs likewise framed the molecule as a ghrelin receptor agonist acting on that pathway (PMID 29468076).

From that single receptor interaction, the literature traces several downstream branches: pituitary growth hormone release, hypothalamic appetite circuitry, metabolic signalling that shows up as short-term changes in glucose measures, and effects on gastrointestinal motility observed in rodent models. Some of those branches are well established as receptor pharmacology; others remain proposed explanations for observed outcomes. This page separates the two and labels animal work as animal work.

The receptor target: GHSR-1a

GHSR-1a is a G protein coupled receptor. In the canonical description of this receptor family, agonist binding couples predominantly through Gq/11 proteins, activating phospholipase C, generating inositol trisphosphate and diacylglycerol, and raising intracellular calcium in the target cell. In pituitary somatotrophs, that calcium rise is the trigger for growth hormone secretion. The receptor is also notable for high constitutive (ligand-independent) activity, which is one reason pharmacologists distinguish between full agonism, partial agonism and inverse agonism at this site.

Receptor distribution matters for understanding why one molecule produces effects in several organ systems. GHSR-1a is expressed in the anterior pituitary, in hypothalamic nuclei involved in energy balance, on vagal afferent neurons, and within parts of the central and enteric nervous systems. Reviews of capromorelin in veterinary medicine connect its appetite-related and growth hormone-related actions to activation of this widely distributed receptor rather than to several unrelated targets (PMID 37493940).

Why oral activity is part of the mechanism story

Ghrelin itself is a peptide requiring acylation for receptor activity and is administered parenterally in experimental settings. Capromorelin belongs to the non-peptide or peptidomimetic secretagogue class developed for oral administration, and published veterinary work has used oral and enteral routes. A study in mice administered capromorelin enterally and examined body weight as the outcome of interest, demonstrating that the enteral route was workable in that species (PMID 39025662). Oral bioavailability is therefore a pharmacokinetic property that shapes how the mechanism is expressed in practice, rather than part of the receptor mechanism itself.

Branch one: growth hormone and the somatotropic axis

The classical effect of GHSR-1a agonism is pulsatile growth hormone release from the anterior pituitary, which in turn raises hepatic insulin-like growth factor 1. The review of capromorelin in veterinary medicine described growth hormone secretagogue activity as central to the compound's pharmacological profile (PMID 37493940). Growth hormone and IGF-1 are the mediators usually invoked when researchers discuss changes in lean tissue and body weight after repeated administration, although that link is an inference drawn from the known biology of the axis rather than a measured chain in every study.

Weight-related observations have been recorded in several species. Researchers investigating broiler chickens reported that capromorelin increased feed intake and body weight gain in that model (PMID 34182219). A mouse study examined body weight after enteral administration (PMID 39025662), and a study in rhesus macaques evaluated both safety and efficacy outcomes in that non-human primate species (PMID 38423529). In companion animals, a randomised, masked, placebo-controlled clinical trial in cats with unintended weight loss reported that capromorelin promoted weight gain relative to placebo (PMID 41204815).

Branch two: appetite and hypothalamic circuitry

Ghrelin receptor activation in the arcuate nucleus of the hypothalamus stimulates neurons expressing neuropeptide Y and agouti-related peptide, the orexigenic population that drives food-seeking behaviour. Vagal afferent signalling from the gastrointestinal tract provides a second route by which the receptor influences central appetite networks. This is the standard textbook account of ghrelin biology and is the mechanism most often proposed to explain the feeding effects seen with capromorelin.

The applied evidence is largely veterinary. A pharmacology paper on capromorelin as a novel therapy for stimulation of appetite in dogs described appetite stimulation as the therapeutic target of ghrelin receptor agonism in that species (PMID 29468076), and the broiler chicken study reported increased feed intake as a measured outcome (PMID 34182219). What the cited studies record is behaviour and intake at the whole-animal level; the hypothalamic neuron-level account remains the proposed explanation layered on top of those observations.

Branch three: glucose and insulin signalling

Growth hormone opposes insulin action in peripheral tissues, so any growth hormone secretagogue raises reasonable questions about glucose handling. Investigators have addressed this directly. A study of glycemic control in healthy dogs examined glucose-related variables after capromorelin administration (PMID 35689953), and a separate study of the ghrelin receptor agonist capromorelin in healthy cats evaluated glucose metabolism in that species (PMID 32619812). Both were designed around short-term metabolic measurement in healthy animals rather than long-term metabolic disease endpoints, and both sit within the mechanistic picture of a growth hormone secretagogue acting on an axis that intersects with glucose regulation.

Branch four: gastrointestinal motility

A distinct body of rodent work has explored ghrelin receptor agonism as a prokinetic mechanism. Researchers reported that a centrally acting ghrelin receptor agonist stimulated defecation in spinal cord-injured rats, implicating central and spinal circuitry rather than purely local gut action (PMID 21625243). A later study reported that a ghrelin receptor agonist acted as an effective colokinetic in rats with diet-induced constipation (PMID 25616061). Work in a rat model of Parkinson's disease produced by lesion of nigrostriatal dopaminergic neurons investigated the nerve pathways mediating colorectal dysfunction (PMID 32512642).

The mechanistic reading of this cluster is that GHSR-1a expressed in the lumbosacral defecation centre and associated autonomic pathways can be engaged to increase colorectal motor activity. All of this evidence is from rodents, and none of it establishes an equivalent pathway in companion animals or in people.

Established mechanism versus proposed mechanism

Safety observations in published studies: What Studies Report

Mechanism and tolerability are linked, because effects on the growth hormone axis and on gastrointestinal signalling are the same biology that generates observable reactions. Researchers evaluated the safety of daily administration of capromorelin in cats across a dedicated study (PMID 29057482), and a study in rhesus macaques assessed safety alongside efficacy (PMID 38423529). The veterinary review summarised safety alongside efficacy and clinical applications of the ghrelin receptor agonist in that field (PMID 37493940). Metabolic monitoring studies in healthy dogs and healthy cats examined glucose-related parameters specifically because of the growth hormone connection (PMID 35689953, PMID 32619812). Interpretation of any individual finding for a specific animal or person belongs with a licensed prescribing clinician.

Regulatory standing and the limits of the evidence

Capromorelin's established regulatory footprint is in veterinary medicine, where it is handled as a prescription product and where its clinical applications have been reviewed in the veterinary literature (PMID 37493940). In human medicine, the molecule's history sits in the investigational clinical research stage. Readers comparing species should keep three limits in mind. First, most published mechanism-relevant data come from rodents, chickens, dogs, cats and non-human primates, and receptor-level similarity does not guarantee identical whole-organism responses. Second, the strongest controlled clinical evidence cited here is the randomised, masked, placebo-controlled feline trial in cats with unintended weight loss (PMID 41204815). Third, the colonic motility literature used constipation and neurological injury models in rats, which are mechanistic probes rather than general statements about digestive function (PMID 25616061).

A broader plain-language overview of this molecule is available on the PeptideU learn page for capromorelin, which covers the wider evidence base rather than the mechanism alone.

This page is for educational purposes only and is not medical advice; consult a licensed physician or, for animals, a licensed veterinarian about any question involving diagnosis, prescribing or use. No dosing directions appear on this page, and nothing here describes what any reader should do.

References

• Insights on discovery, efficacy, safety and clinical applications of ghrelin receptor agonist capromorelin in veterinary medicine (Veterinary Research Communications, 2024)
• Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs (Veterinary Medicine and Science, 2018)
• Capromorelin, a ghrelin receptor agonist, increases feed intake and body weight gain in broiler chickens (Poultry Science, 2021)
• Investigating the Effect of Enterally Administered Capromorelin on Body Weight in Mice (Comparative Medicine, 2024)
• Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (JAALAS, 2024)
• Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial (Journal of Feline Medicine and Surgery, 2025)
• Evaluation of the safety of daily administration of capromorelin in cats (Journal of Veterinary Pharmacology and Therapeutics, 2018)
• The effect of capromorelin on glycemic control in healthy dogs (Domestic Animal Endocrinology, 2022)
• The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats (Domestic Animal Endocrinology, 2021)
• Stimulation of defecation in spinal cord-injured rats by a centrally acting ghrelin receptor agonist (Spinal Cord, 2011)
• A ghrelin receptor agonist is an effective colokinetic in rats with diet-induced constipation (Neurogastroenterology and Motility, 2015)
• Investigation of nerve pathways mediating colorectal dysfunction in Parkinson's disease model produced by lesion of nigrostriatal dopaminergic neurons (Neurogastroenterology and Motility, 2020)